Bet_Noire Iterum Therapeutics ( NASDAQ: ITRM ) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs. The drug, which is Iterum’s first FDA-approved product, is indicated for treatment of uUTIs.
Back to Health Page
